Straits Research released its highly anticipated report, “Global Oncology-Based Preclinical CRO Market Size & Outlook, 2026-2034.” According to the study, the global market size is valued at USD 543.55 million in 2025 and is projected to expand to USD 1716.36 million by 2034, registering a compound annual growth rate (CAGR) of 13.67%.

Market Dynamics

The global oncology-based preclinical CRO market is driven by the increasing prevalence of cancer worldwide, rising demand for targeted therapies and immuno-oncology drugs, and growing outsourcing of preclinical studies to contract research organizations offering specialized in vitro and in vivo oncology models. Additionally, advancements in biomarker analysis, translational research, and the integration of AI and 3D organoid models are further accelerating market growth. However, the market faces restraints such as the high cost of complex preclinical studies, stringent regulatory and ethical guidelines for animal testing, and challenges in translating preclinical results to clinical success. Nevertheless, expanding R&D investments, increasing collaborations between pharma companies and CROs, and the emergence of cost-effective outsourcing destinations in the Asia-Pacific present significant opportunities for market expansion and innovation.

Market Highlights

• Type: The solid tumors segment dominated the market in 2025, with a revenue share of 52.34%.
• Application: The in vivo segment is anticipated to register the fastest CAGR of 14.88%.
• Regional Insights: North America dominates the market with 47.78 % share, driven by the strong presence of leading pharmaceutical and biotechnology companies, well-established research infrastructure, and increasing investments in oncology drug development.